Skip to main content

Join FDA and DiMe during a 2-day virtual event.

Accountability for the Diversity Plan to Improve Enrollment of Underrepresented Populations in Clinical Trials


November 30, 2022


Del Smith

Co-founder and CEO, Acclinate

Ingrid Oakley-Girvan

SVP of Research and Strategy, Medable

Ricki Fairley

CEO, Touch, The Black Breast Cancer Alliance

Racquel Racadio

Director, Global Representation in Clinical Research, Amgen

Ed Ramos

Director, Digital Clinical Trials at Scripps Research and Principal Science Officer at CareEvolution, Inc

MIchel Reid

Sr. Director and Head, Global Demographics & Diversity, GSK

Sam Eells

Co-Founder at Lightship


Jonah Comstock

Editor in Chief, Pharmaphorum

Discussion Topic

Everyone’s talking about the lack of diversity, equity, and inclusion in clinical trials. The FDA issued draft guidance to provide recommendations to help clinical trial sponsors develop a Race and Ethnicity Diversity Plan. Some House Democrats are also pushing for Congressional legislation to secure more representation in clinical trials. We all recognize the need to do something about it, but who’s going to lead the efforts? Who’s going to be accountable for increasing diversity in clinical trials?

Leaders from across the clinical trials ecosystem give an update on the Diversity, Equity, and Inclusion in Digitized Clinical Trials project, and an in-depth discussion on what different stakeholders can do to ensure digital technologies are used to increase diversity, equity, and inclusion in clinical trials.

Watch the webinar

View the slides

Join our next project

Help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients

Join the Integrated Evidence Plans project

Join us
Not today